We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
-21.57%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$47.9M
(-22%)
Cap. Flow
+$7.45M
Cap. Flow % of AUM
Cap. Flow %
4.46%
Top 10 Holdings %
Top 10 Hldgs %
98.53%
Holding
14
New
2
Increased
–
Reduced
2
Closed
1
Avg Time Held
0.9
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EVAR
Lombard Medical
EVAR
|
+$22.2M |
| 2 |
EPRS
Epirus Biopharmaceuticals
EPRS
|
+$68.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals
PTLA
|
+$8.17M |
| 2 |
Supernus Pharmaceuticals
SUPN
|
+$6.51M |
| 3 |
ZLCS
Zalicus
ZLCS
|
+$96K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.7% |
| 2 | Miscellaneous | 32.3% |
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q3 2014 Portfolio in Review
As of Q3 2014, Abingworth held 14 positions worth $167M, down 22% from $215M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Abingworth deployed $7.45M of net new capital in Q3 2014, opening 2 new positions. Its largest new stake was Lombard Medical: 3,352,544 shares worth $25.6M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Portola Pharmaceuticals, an estimated $8.17M trimmed.
- Abingworth's largest Q3 2014 buy was Lombard Medical: 3,352,544 shares worth $25.6M.
- Abingworth's biggest Q3 2014 reduction was Portola Pharmaceuticals, cutting an estimated $8.17M.
- Abingworth fully exited Zalicus in Q3 2014, selling an estimated $96K.
- Abingworth's ten largest holdings make up 99% of its $167M portfolio in Q3 2014.
- Abingworth opened 2 new positions and closed 1 in Q3 2014.
- Abingworth's portfolio value fell 22% quarter-over-quarter to $167M.
Based on Abingworth's 13F filing for Q3 2014, filed 14 Nov 2014.